Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFZBNE)

• Drug Name: ITF2357 Drug Info
• Synonyms: Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)

Indication

Disease Entry	ICD 11	Status	REF
Duchenne dystrophy	8C70	Phase 3	[1]
Essential thrombocythemia	3B63.1Z	Phase 2	[2]
Myelofibrosis	2A20.2	Phase 2	[2]
Polycythemia vera	2A20.4	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 9804992
  ChEBI ID: CHEBI:94187
  CAS Number: CAS 497833-27-9
  TTD Drug ID: DMFZBNE

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 2 (JAK-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Approved	[4]
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[5]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[6]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Approved	[7]
Fedratinib	DM4ZBK6	Myelofibrosis	2A20.2	Approved	[8]
XL019	DMJ6F5C	Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[9]
CTP-543	DM3SYOK	Alopecia	ED70	Phase 2	[10]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[11]
CTP-543	DM3SYOK	Alopecia	ED70	Phase 2	[12]

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[13]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[14]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[15]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[16]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[17]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[15]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[18]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[19]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[20]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[15]

Drug(s) Targeting Histone deacetylase 1 (HDAC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[21]
Romidepsin	DMT5GNL	Cutaneous T-cell lymphoma	2B01	Approved	[22]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[21]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[20]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[23]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[17]
Phenylbutyrate	DMBHPDW	Urea cycle disorder	5C50.A	Phase 2	[24]
MGCD-0103	DM726HX	Non-small-cell lung cancer	2C25.Y	Phase 2	[21]
Resminostat	DMNE1FR	Hepatocellular carcinoma	2C12.02	Phase 2	[25]
Sodium butyrate	DMKNIVG	Acute myeloid leukaemia	2A60	Phase 2	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[1]
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[3]
Janus kinase 2 (JAK-2)	TTRMX3V	JAK2_HUMAN	Inhibitor	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7490).
• [3] Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
• [4] Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
• [5] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [6] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [7] National Cancer Institute Drug Dictionary (drug id 609888).
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [9] Company report (Portola Pharmaceuticals)
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
• [12] Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
• [13] Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
• [14] Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
• [17] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [18] US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
• [19] Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
• [20] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [21] Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
• [22] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [23] NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
• [24] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [25] 2011 Pipeline of 4SC AG.
• [26] Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.